Registro:

Referencias:

• Fischereder, M., Kretzler, M., New immunosuppressive strategies in renal transplant recipients (2004) J Nephrol, 17, pp. 9-16
• Dambrin, C., Klupp, J., Morris, R.E., Pharmacodynamics of immunosuppressive drugs (2000) Curr Opin Immunol, 12, pp. 557-562
• Armstrong, V.W., Oellerich, M., New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine (2001) Clin Biochem, 34, pp. 9-16
• Myers, B.D., Sibley, R., Newton, L., Tomlanovich, S.J., Boshkos, C., Stinson, E., The long-term course of cyclosporine-associated chronic nephropathy (1988) Kidney Int, 33, pp. 590-600
• Kasiske, B.L., Tortorice, K.L., Heim-Duthoy, K.L., Awni, W.M., Rao, K.V., The adverse impact of cyclosporine on serum lipids in renal transplant recipients (1991) Am J Kidney Dis, 17, pp. 700-707
• Del Tacca, M., Prospects for personalized immunosuppression: Pharmacologic tools-a review (2004) Transplant Proc, 36, pp. 687-689
• Swartz, S.L., Dluhy, R.G., Corticosteroids: Clinical pharmacology and therapeutic use (1978) Drugs, 16, pp. 238-255
• Barnes, P.J., Adcock, I.M., Transcription factors and asthma (1998) Eur Respir J, 12, pp. 221-234
• Boumpas, D.T., Chrousos, G.P., Wilder, R.L., Cupps, T.R., Balow, J.E., Glucocorticoid therapy for immune-mediated diseases: Basic and clinical correlates (1993) Ann Intern Med, 119, pp. 1198-1208
• Ashwell, J.D., Lu, F.W., Vacchio, M.S., Glucocorticoids in T cell development and function (2000) Annu Rev Immunol, 18, pp. 309-345
• Sapolsky, R.M., Romero, L.M., Munck, A.U., How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions (2000) Endocr Rev, 21, pp. 55-89
• Refojo, D., Liberman, A.C., Giacomini, D., Carbia Nagashima, A., Graciarena, M., Echenique, C., Integrating systemic information at the molecular level: Cross-talk between steroid receptors and cytokine signaling on different target cells (2003) Ann N Y Acad Sci, 992, pp. 196-204
• De Bosscher, K., Vanden Berghe, W., Haegeman, G., Mechanisms of anti-inflammatory action and of immunosuppression by gluococorticoids: Negative interference of activated glucocorticoid receptor with transcription factors (2000) J Neuroimmunol, 109, pp. 16-22
• Liberman, A.C., Druker, J., Perone, M.J., Arzt, E., Glucocorticoids in the regulation of transcription factors that control cytokine synthesis (2007) Cytokine Growth Factor Rev, 18, pp. 45-56
• Beato, M., Gene regulation by steroid hormones (1989) Cell, 56, pp. 335-344
• Schoenmakers, E., Verrijdt, G., Peeters, B., Verhoeven, G., Rombauts, W., Claessens, F., Differences in ADN binding characteristics of the androgen and glucocorticoid receptors can determine hormone-specific responses (2000) J Biol Chem, 275, pp. 12290-12297
• Pratt, W.B., Toft, D.O., Steroid receptor interactions with heat shock protein and immunophilin chaperones (1997) Endocr Rev, 18, pp. 306-360
• Dittmar, K.D., Demady, D.R., Stancato, L.F., Krishna, P., Pratt, W.B., Folding of the glucocorticoid receptor by the heat shock protein (hsp) 90-based chaperone machinery. The role of p23 is to stabilize receptor.hsp90 heterocomplexes formed by hsp90.p60.hsp70 (1997) J Biol Chem, 272, pp. 21213-21220
• Davies, T.H., Ning, Y.M., Sanchez, E.R., A new first step in activation of steroid receptors: Hormone-induced switching of FKBP51 and FKBP52 immunophilins (2002) J Biol Chem, 277, pp. 4597-4600
• De Bosscher, K., Vanden Berghe, W., Haegeman, G., The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator protein-l: Molecular mechanisms for gene repression (2003) Endocr Rev, 24, pp. 488-522
• Beato, M., Chalepakis, G., Schauer, M., Slater, E.P., ADN regulatory elements for steroid hormones (1989) J Steroid Biochem, 32, pp. 737-747
• Geserick, C., Meyer, H.A., Haendler, B., The role of ADN response elements as allosteric modulators of steroid receptor function (2005) Mol Cell Endocrinol, 236, pp. 1-7
• Auphan, N., DiDonato, J.A., Rosette, C., Helmberg, A., Karin, M., Immunosuppression by glucocorticoids: Inhibition of NF-kappa B activity through induction of I kappa B synthesis (1995) Science, 270, pp. 286-290
• Scheinman, R.I., Gualberto, A., Jewell, C.M., Cidlowski, J.A., Baldwin Jr., A.S., Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors (1995) Mol Cell Biol, 15, pp. 943-953
• Drouin, J., Maira, M., Philips, A., Novel mechanism of action for Nur77 and antagonism by glucocorticoids: A convergent mechanism for CRH activation and glucocorticoid repression of POMC gene transcription (1998) J Steroid Biochem Mol Biol, 65, pp. 59-63
• Novac, N., Baus, D., Dostert, A., Heinzel, T., Competition between glucocorticoid receptor and NFkappaB for control of the human FasL promoter (2006) Faseb J, 20, pp. 1074-1081
• Ray, A., Prefontaine, K.E., Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor (1994) Proc Natl Acad Sci USA, 91, pp. 752-756
• Wissink, S., van Heerde, E.C., vand der, Burg, B., van der, Saag, P.T., A dual mechanism mediates repression of NF-kappaB activity by glucocorticoids (1998) Mol Endocrinol, 12, pp. 355-363
• Caldenhoven, E., Liden, J., Wissink, S., Van de Stolpe, A., Raaijmakers, J., Koenderman, L., Negative cross-talk between RelA and the glucocorticoid receptor: A possible mechanism for the antiinflammatory action of glucocorticoids (1995) Mol Endocrinol, 9, pp. 401-412
• Liberman, A.C., Refojo, D., Druker, J., Toscano, M., Rein, T., Holsboer, F., The activated glucocorticoid receptor inhibits the transcription factor T-bet by direct protein-protein interaction (2007) Faseb J, 21, pp. 1177-1188
• Helmberg, A., Auphan, N., Caelles, C., Karin, M., Glucocorticoid-induced apoptosis of human leukemic cells is caused by the repressive function of the glucocorticoid receptor (1995) Embo J, 14, pp. 452-460
• Jonat, C., Rahmsdorf, H.J., Park, K.K., Cato, A.C., Gebel, S., Ponta, H., Antitumor promotion and antiinflammation: Down-modulation of AP-1 (Fos/ Jun) activity by glucocorticoid hormone (1990) Cell, 62, pp. 1189-1204
• Schule, R., Rangarajan, P., Kliewer, S., Ransone, L.J., Bolado, J., Yang, N., Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor (1990) Cell, 62, pp. 1217-1226
• Nissen, R.M., Yamamoto, K.R., The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain (2000) Genes Dev, 14, pp. 2314-2329
• Shaw, A.S., Dustin, M.L., Making the T cell receptor go the distance: A topological view of T cell activation (1997) Immunity, 6, pp. 361-369
• Stoddard, B.L., Flick, K.E., Calcineurin-immunosuppressor complexes (1996) Curr Opin Struct Biol, 6, pp. 770-775
• Handschumacher, R.E., Harding, M.W., Rice, J., Drugge, R.J., Speicher, D.W., Cyclophilin: A specific cytosolic binding protein for cyclosporin A (1984) Science, 226, pp. 544-547
• Liu, J., Farmer Jr., J.D., Lane, W.S., Friedman, J., Weissman, I., Schreiber, S.L., Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes (1991) Cell, 66, pp. 807-815
• Reynolds, N.J., Al-Daraji, W.I., Calcineurin inhibitors and sirolimus: Mechanisms of action and applications in dermatology (2002) Clin Exp Dermatol, 27, pp. 555-561
• Hoffmann, M., Rychlewski, J., Chrzanowska, M., Hermann, T., Mechanism of activation of an immunosuppressive drug, azathioprine. Quantum chemical study on the reaction of azathioprine with cysteine (2001) J Am Chem Soc, 123, pp. 6404-6409
• Poppe, D., Tiede, I., Fritz, G., Becker, C., Bartsch, B., Wirtz, S., Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins (2006) J Immunol, 176, pp. 640-651
• Tiede, I., Fritz, G., Strand, S., Poppe, D., Dvorsky, R., Strand, D., CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes (2003) J Clin Invest, 111, pp. 1133-1145
• Murata, M., Suzuki, T., Midorikawa, K., Oikawa, S., Kawanishi, S., Oxidative ADN damage induced by a hydroperoxide derivative of cyclophosphamide (2004) Free Radio Biol Med, 37, pp. 793-802
• Chen, C.S., Jounaidi, Y., Su, T., Waxman, D.J., Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model (2007) Cancer Gene Ther
• Chen, L., Yu, L.J., Waxman, D.J., Potentiation of cytochrome P450/ cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene (1997) Cancer Res, 57, pp. 4830-4837
• Schwartz, P.S., Waxman, D.J., Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells (2001) Mol Pharmacol, 60, pp. 1268-1279
• Sabatini, D.M., Erdjument-Bromage, H., Lui, M., Tempst, P., Snyder, S.H., RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs (1994) Cell, 78, pp. 35-43
• Lorenz, M.C., Heitman, J., TOR mutations confer rapamycin resistance by preventing interaction with FKBP12-rapamycin (1995) J Biol Chem, 270, pp. 27531-27537
• Alarcon, C.M., Heitman, J., Cardenas, M.E., Protein kinase activity and identification of a toxic effector domain of the target of rapamycin TOR proteins in yeast (1999) Mol Biol Cell, 10, pp. 2531-2546
• Allison, A.C., Eugui, E.M., Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF) (1996) Clin Transplant, 10, pp. 77-84
• Allison, A.C., Eugui, E.M., Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection (2005) Transplantation, 80, pp. S181-S190
• Breedveld, F.C., Dayer, J.M., Leflunomide: Mode of action in the treatment of rheumatoid arthritis (2000) Ann Rheum Dis, 59, pp. 841-849
• Manna, S.K., Aggarwal, B.B., Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression (1999) J Immunol, 162, pp. 2095-2102
• Yao, H.W., Li, J., Chen, J.Q., Xu, S.Y., A 771726, the active metabolite of leflunomide, inhibits TNF-alpha and IL-1 from Kupffer cells (2004) Inflammation, 28, pp. 97-103
• Pietra, B.A., Boucek, M.M., Immunosuppression for pediatric cardiac transplantation in the modern era (2000) Prog Pediatr Cardiol, 11, pp. 115-129
• Alegre, M.L., Peterson, L.J., Xu, D., Sattar, H.A., Jeyarajah, D.R., Kowalkowski, K., A non-activating "humanized" anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo (1994) Transplantation, 57, pp. 1537-1543
• Xu, D., Alegre, M.L., Varga, S.S., Rothermel, A.L., Collins, A.M., Pulito, V.L., In vitro characterization of five humanized OKT3 effector function variant antibodies (2000) Cell Immunol, 200, pp. 16-26
• Kuus-Reichel, K., Grauer, L.S., Karavodin, L.M., Knott, C., Krusemeier, M., Kay, N.E., Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies? (1994) Clin Diagn Lab Immunol, 1, pp. 365-372
• Tsurushita, N., Hinton, P.R., Kumar, S., Design of humanized antibodies: From anti-Tac to Zenapax (2005) Methods, 36, pp. 69-83
• Kanda, H., Mori, K., Koga, H., Taniguchi, K., Kobayashi, H., Sakahara, H., Construction and expression of chimeric antibodies by a simple replacement of heavy and light chain V genes into a single cassette vector (1994) Hybridoma, 13, pp. 359-366
• Chapman, T.M., Keating, G.M., Basiliximab: A review of its use as induction therapy in renal transplantation (2003) Drugs, 63, pp. 2803-2835
• Waldmann, T.A., Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: A 25-year personal odyssey (2007) J Clin Immunol, 27, pp. 1-18

Citas:

---------- APA ----------

---------- CHICAGO ----------

---------- MLA ----------

---------- VANCOUVER ----------